Skip to main content
SpringerLink
Log in

Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 211))

Abstract

Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRα), and RET and KIT proto-oncogenes. Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer and in combination with everolimus for the treatment of advanced renal cell carcinoma following anti-VEGF treatment. In hepatocellular carcinoma lenvatinib was non inferior to sorafenib in first line with an improved progression-free survival and approval in this indication is expected. Lenvatinib is currently investigated for further indications as single agent and in combinations. Side effects include typical TKI induced toxicities such as hypertension, diarrhea, hypothyroidism, and fatigue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Boss DS et al (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106(10):1598–1604. ISSN 1532-1827. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/22516948

  • Bruheim S et al (2011) Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer 129(3):742–750. ISSN 1097-0215. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21225632

  • Cabanillas ME et al (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16):2749–2756. ISSN 1097-0142. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25913680

  • Finn RS, Cheng A-L, Ikeda K et al (2017) A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. ASCO

    Google Scholar 

  • Flaherty KT et al (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 33(21):2384–2391. ISSN 1527-7755. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26077237

  • Guo H et al (2015) The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics 42(7):343–353. ISSN 1673-8527. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26233890

  • Gupta A et al (2016) Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 81(6):1124–1133. ISSN 1365-2125. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26879594

  • Hickey MM, Simon MC (2006) Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 76:217–257. ISSN 0070-2153. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/17118268

  • Hong DS et al (2015) Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget 6(40):43127–43134. ISSN 1949-2553. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26503473

  • Ikeda M et al (2016) Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res 22(6):1385–1394. ISSN 1078-0432. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26500236

  • Ikeda K et al (2017) Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52(4):512–519. ISSN 1435-5922. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/27704266

  • Ikuta K et al (2009) E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 15(23):7229–7237. ISSN 1078-0432. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/19934291

  • Klein M et al (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86(2):656–658. ISSN 0021-972X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/11158026

  • Leonetti A et al (2017) Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. Ther Clin Risk Manag 13:799–806. ISSN 1176-6336. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28721060

  • Matsui J et al (2008a) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14(17):5459–5465. ISSN 1078-0432. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/18765537

  • Matsui J et al (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122(3):664–671. ISSN 1097-0215. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/17943726

  • Nishio M et al (2013) Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer 109(3):538–544. ISSN 1532-1827. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/23860537

  • Ogino H et al (2011) E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 10(7):1218–1228. ISSN 1538-8514. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21551260

  • Okamoto K et al (2015) Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett 6(1):89–94. ISSN 1948-5875. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25589937

  • Ravaud A et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 26(7):1378–1384. ISSN 1569-8041. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25851632

  • Rini BI et al (2014) Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32(8):752–759. ISSN 1527-7755. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24297945

  • Schlumberger M et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630. ISSN 1533-4406. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25671254

  • Schlumberger M et al (2016) A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res 22(1):44–53. ISSN 1078-0432. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26311725

  • Shumaker RC et al (2014) Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol 73(6):1109–1117. ISSN 1432-0843. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/24658627

  • Shumaker R et al (2015) Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol 55(3):317–327. ISSN 1552-4604. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25204557

  • Tamai T et al (2017) Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol 57(9):1138–1147. ISSN 1552-4604. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/28561918

  • Tohyama O et al (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. ISSN 2090-8067. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25295214

  • Wiegering A et al (2014) E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. Neoplasia 16(11):972–981. ISSN 1476-5586. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25425971

  • Yamada K et al (2011) Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 17(8):2528–2537. ISSN 1078-0432. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21372218

  • Yamamoto Y et al (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18. ISSN 2045-824X. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25197551

Download references

Author information

Authors and Affiliations

  1. National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg University Medical Center, Im Neuenheimer Feld 460, D-69120, Heidelberg, Germany

    Stefanie Zschäbitz & Carsten Grüllich

Authors
  1. Stefanie Zschäbitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carsten Grüllich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Grüllich .

Editor information

Editors and Affiliations

  1. MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Baden-Württemberg, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zschäbitz, S., Grüllich, C. (2018). Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 211. Springer, Cham. https://doi.org/10.1007/978-3-319-91442-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91442-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91441-1

  • Online ISBN: 978-3-319-91442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation